FDA Creates a New Advisory Committee for Genetic Metabolic Diseases – Could This Be an Opportunity to Support Rare Disease Product Development More Broadly?
FDA Law Blog
DECEMBER 13, 2023
Janet Maynard, Director of this Office, highlighted in the press release that “[g]enetic metabolic diseases include very rare diseases that individually affect a limited number of patients. GeMDAC’s mandate is to advise the Agency on these complicated issues in this challenging area of medical product development.
Let's personalize your content